Published in Am J Physiol Gastrointest Liver Physiol on October 28, 2011
Cardiovascular biology of the incretin system. Endocr Rev (2012) 2.42
Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease. PLoS One (2015) 1.68
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. J Diabetes Investig (2013) 1.55
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol (2015) 1.50
Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? World J Gastroenterol (2014) 0.93
Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. Br J Pharmacol (2014) 0.90
Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis. J Nutr Biochem (2014) 0.88
Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats. Cardiovasc Diabetol (2014) 0.87
Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix. Basic Res Cardiol (2015) 0.85
Targeting metabolic disturbance in the diabetic heart. Cardiovasc Diabetol (2015) 0.84
Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease. PLoS One (2014) 0.84
Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis. Med Mol Morphol (2013) 0.84
Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open (2013) 0.83
The relationship between visceral adiposity and left ventricular diastolic function: results from the Baltimore Longitudinal Study of Aging. Nutr Metab Cardiovasc Dis (2013) 0.83
The role of gastrointestinal hormones in hepatic lipid metabolism. Semin Liver Dis (2013) 0.83
Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids. Acta Pharm Sin B (2015) 0.81
Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. BMC Med (2012) 0.81
Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2015) 0.80
Liraglutide reduces lipid accumulation in steatotic L‑02 cells by enhancing autophagy. Mol Med Rep (2014) 0.80
Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats. World J Gastroenterol (2014) 0.79
The cardiometabolic benefits of glycine: Is glycine an 'antidote' to dietary fructose? Open Heart (2014) 0.78
Novel Pharmacotherapy Options for NASH. Dig Dis Sci (2016) 0.78
Prophylactic effects of the glucagon-like Peptide-1 analog liraglutide on hyperglycemia in a rat model of type 2 diabetes mellitus associated with chronic pancreatitis and obesity. Comp Med (2014) 0.78
Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1. Open Heart (2015) 0.77
GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance. Mol Metab (2014) 0.77
The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities. BMB Rep (2016) 0.76
Comparison of the efficacy of liraglutide with pioglitazone on dexamethasone induced hepatic steatosis, dyslipidemia and hyperglycaemia in albino rats. Indian J Pharmacol (2015) 0.75
C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis. Lab Invest (2016) 0.75
Extrapancreatic effects of incretin hormones: evidence for weight-independent changes in morphological aspects and oxidative status in insulin-sensitive organs of the obese nondiabetic Zucker rat (ZFR). Physiol Rep (2016) 0.75
Panhypopituitarism due to Absence of the Pituitary Stalk: A Rare Aetiology of Liver Cirrhosis. Case Rep Endocrinol (2016) 0.75
High fructose causes cardiac hypertrophy via mitochondrial signaling pathway. Am J Transl Res (2016) 0.75
Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure. Int J Obes Suppl (2016) 0.75
Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA (2004) 25.36
Lifetime risk for diabetes mellitus in the United States. JAMA (2003) 10.33
Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care (2001) 9.76
A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell (1998) 8.10
Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell (2000) 7.26
Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest (2007) 3.88
Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes (2006) 3.69
Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol (2010) 3.36
Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology (2010) 3.11
Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.89
Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol (2010) 2.75
Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol (2009) 2.75
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes (2005) 2.64
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes (2009) 2.58
The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. J Appl Genet (2006) 2.57
Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol (2008) 2.45
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology (2006) 2.08
Fat, carbohydrate, and calories in the development of diabetes and obesity in the C57BL/6J mouse. Metabolism (2004) 2.04
Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem (2009) 2.00
Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. J Lipid Res (2008) 1.91
Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology (2010) 1.86
Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol (2007) 1.75
Reversal of diet-induced obesity and diabetes in C57BL/6J mice. Metabolism (1998) 1.67
Trans fats in America: a review of their use, consumption, health implications, and regulation. J Am Diet Assoc (2010) 1.64
Microsomal triglyceride transfer protein. Biochim Biophys Acta (1997) 1.60
Liver fatty acid-binding protein and obesity. J Nutr Biochem (2010) 1.59
Role of fatty acid binding proteins and long chain fatty acids in modulating nuclear receptors and gene transcription. Lipids (2007) 1.59
Diet-induced changes in uncoupling proteins in obesity-prone and obesity-resistant strains of mice. Proc Natl Acad Sci U S A (1998) 1.49
Compensatory increase in hepatic lipogenesis in mice with conditional intestine-specific Mttp deficiency. J Biol Chem (2005) 1.43
The role of lipid metabolism in the pathogenesis of alcoholic and nonalcoholic hepatic steatosis. Semin Liver Dis (2010) 1.41
Microsomal triglyceride transfer protein in plasma and cellular lipid metabolism. Curr Opin Lipidol (2008) 1.40
Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis (2010) 1.40
Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology (2009) 1.39
GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One (2011) 1.26
The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology (2008) 1.26
Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther (2005) 1.22
Impaired glucose tolerance and predisposition to the fasted state in liver glycogen synthase knock-out mice. J Biol Chem (2010) 1.12
Good fat/bad fat. Hepatology (2007) 1.10
Glucose regulates fatty acid binding protein interaction with lipids and peroxisome proliferator-activated receptor α. J Lipid Res (2010) 0.99
Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model. J Hepatol (2010) 0.97
FABPs as determinants of myocellular and hepatic fuel metabolism. Mol Cell Biochem (2007) 0.96
The blind men 'see' the elephant-the many faces of fatty liver disease. World J Gastroenterol (2008) 0.94
GLP-1 amplifies insulin signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1 adipocytes. Endocrine (2007) 0.92
The action of GLP-1 and exendins upon glucose transport in normal human adipocytes, and on kinase activity as compared to morbidly obese patients. Int J Mol Med (2007) 0.90
Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. J Mol Endocrinol (2005) 0.89
Negative correlation between neuropeptide Y/agouti-related protein concentration and adiponectinemia in nonalcoholic fatty liver disease obese adolescents submitted to a long-term interdisciplinary therapy. Metabolism (2009) 0.86
Oleate-mediated stimulation of microsomal triglyceride transfer protein (MTP) gene promoter: implications for hepatic MTP overexpression in insulin resistance. Biochemistry (2005) 0.82
NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res (2005) 4.66
Nox4 is required for maintenance of the differentiated vascular smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol (2006) 3.13
Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol (2002) 3.10
Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care (2011) 3.06
Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res (2007) 2.50
Hemodynamic shear stresses in mouse aortas: implications for atherogenesis. Arterioscler Thromb Vasc Biol (2006) 2.34
Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology (2007) 2.25
Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology (2002) 2.10
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology (2006) 2.08
Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila) (2012) 1.90
Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology (2010) 1.86
Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology (2005) 1.81
An assessment of statin safety by hepatologists. Am J Cardiol (2006) 1.78
Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res (2008) 1.67
Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast Cancer Res (2012) 1.65
Inactivation of focal adhesion kinase in cardiomyocytes promotes eccentric cardiac hypertrophy and fibrosis in mice. J Clin Invest (2005) 1.61
Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res (2006) 1.58
The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol (2005) 1.49
leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3. J Biol Chem (2007) 1.48
Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res (2012) 1.39
Shanthi V. Sitaraman, MD, PhD: physician, scientist, educator, and humanitarian. Gastroenterology (2011) 1.39
Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways. J Biol Chem (2012) 1.37
Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clin Gastroenterol Hepatol (2004) 1.32
GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One (2011) 1.26
FOXO3A regulates peroxiredoxin III expression in human cardiac fibroblasts. J Biol Chem (2008) 1.25
Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology (2010) 1.23
Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology (2010) 1.20
Epstein-Barr virus induced hepatitis: An important cause of cholestasis. Hepatol Res (2005) 1.20
Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells. J Cell Biochem (2003) 1.19
PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes. J Mol Cell Cardiol (2006) 1.17
Role of endoplasmic reticulum stress in age-related susceptibility to lung fibrosis. Am J Respir Cell Mol Biol (2012) 1.14
Med1 plays a critical role in the development of tamoxifen resistance. Carcinogenesis (2012) 1.13
Leptin increases tissue inhibitor of metalloproteinase I (TIMP-1) gene expression by a specificity protein 1/signal transducer and activator of transcription 3 mechanism. Mol Endocrinol (2006) 1.09
Adiponectin activation of AMPK disrupts leptin-mediated hepatic fibrosis via suppressors of cytokine signaling (SOCS-3). J Cell Biochem (2010) 1.07
Resveratrol suppresses angiotensin II-induced Akt/protein kinase B and p70 S6 kinase phosphorylation and subsequent hypertrophy in rat aortic smooth muscle cells. Mol Pharmacol (2002) 1.07
Murine alanine aminotransferase: cDNA cloning, functional expression, and differential gene regulation in mouse fatty liver. Hepatology (2004) 1.06
Mechanism of hydrogen peroxide-induced cell cycle arrest in vascular smooth muscle. Antioxid Redox Signal (2002) 1.06
NADPH oxidases 1 and 4 mediate cellular senescence induced by resveratrol in human endothelial cells. Free Radic Biol Med (2009) 1.04
Benzyl isothiocyanate inhibits oncogenic actions of leptin in human breast cancer cells by suppressing activation of signal transducer and activator of transcription 3. Carcinogenesis (2010) 1.04
Diastolic dysfunction is associated with cardiac fibrosis in the senescence-accelerated mouse. Am J Physiol Heart Circ Physiol (2011) 1.03
Patient perception versus medical record entry of health-related conditions among patients with heart failure. Am J Cardiol (2010) 1.03
Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells. Endocr Relat Cancer (2011) 1.01
Adiponectin inhibits leptin signalling via multiple mechanisms to exert protective effects against hepatic fibrosis. Biochem J (2011) 0.99
Nitrogen doped ZnO thin films prepared by photo-assisted metal-organic chemical vapor deposition. J Nanosci Nanotechnol (2011) 0.96
Downregulation of mitochondrial porin inhibits cell growth and alters respiratory phenotype in Trypanosoma brucei. Eukaryot Cell (2009) 0.95
Cell cycle-dependent regulation of the bi-directional overlapping promoter of human BRCA2/ZAR2 genes in breast cancer cells. Mol Cancer (2010) 0.93
Speckle-tracking strain echocardiography for detecting cardiac dyssynchrony in a canine model of dyssynchrony and heart failure. Am J Physiol Heart Circ Physiol (2007) 0.91
Resveratrol inhibits angiotensin II- and epidermal growth factor-mediated Akt activation: role of Gab1 and Shp2. Mol Pharmacol (2005) 0.91
Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis. J Pharmacol Exp Ther (2009) 0.90
Antagonistic interaction between Wnt and Notch activity modulates the regenerative capacity of a zebrafish fibrotic liver model. Hepatology (2014) 0.90
The prevalence and clinical correlates of nonalcoholic fatty liver disease (NAFLD) in African Americans: the multiethnic study of atherosclerosis (MESA). Dig Dis Sci (2013) 0.88
Inhibition of NF-kappaB signaling reduces virus load and gammaherpesvirus-induced pulmonary fibrosis. Am J Pathol (2010) 0.88
Terbinafine hepatotoxicity resulting in chronic biliary ductopenia and portal fibrosis. Am J Med (2002) 0.87
Mechanistic elucidation of the antitumor properties of withaferin a in breast cancer. Cancer Res (2014) 0.87
Smad3 mediates angiotensin II- and TGF-beta1-induced vascular fibrosis: Smad3 thickens the plot. Circ Res (2006) 0.86
Resveratrol increases serine15-phosphorylated but transcriptionally impaired p53 and induces a reversible DNA replication block in serum-activated vascular smooth muscle cells. Mol Pharmacol (2003) 0.85
Prevalence, quality of care, and complications in long term care residents with diabetes: a multicenter observational study. J Am Med Dir Assoc (2013) 0.85
High-fat feeding in cardiomyocyte-restricted PPARdelta knockout mice leads to cardiac overexpression of lipid metabolic genes but fails to rescue cardiac phenotypes. J Mol Cell Cardiol (2009) 0.85
NEMO binding domain of IKK-2 encompasses amino acids 735-745. J Mol Recognit (2006) 0.84
Dysregulated iron homeostasis is strongly associated with multiorgan failure and early mortality in acute-on-chronic liver failure. Hepatology (2015) 0.83
Integral role of PTP1B in adiponectin-mediated inhibition of oncogenic actions of leptin in breast carcinogenesis. Neoplasia (2013) 0.83
The role of gastrointestinal hormones in hepatic lipid metabolism. Semin Liver Dis (2013) 0.83
Inactivation of a gene for a fibronectin-binding protein of the oral bacterium Streptococcus mutans partially impairs its adherence to fibronectin. Microb Pathog (2008) 0.83
Clinical and transthoracic echocardiographic predictors of abnormal transesophageal findings in patients with suspected cardiac source of embolism. Am J Med Sci (2003) 0.81
Cardiomyocyte-Restricted Deletion of PPARβ/δ in PPARα-Null Mice Causes Impaired Mitochondrial Biogenesis and Defense, but No Further Depression of Myocardial Fatty Acid Oxidation. PPAR Res (2011) 0.79
Glial cell line-derived neurotrophic factor protects against high-fat diet-induced obesity. Am J Physiol Gastrointest Liver Physiol (2014) 0.78
Treatment of fibrosis in nonalcoholic fatty liver disease. Curr Gastroenterol Rep (2007) 0.78
Chlorzoxazone as a cause of acute liver failure requiring liver transplantation. Dig Dis Sci (2007) 0.77
Adiponectin and alcoholic fatty liver: Is it, after all, about what you eat? Hepatology (2005) 0.77
[Association of Pro12Ala variant in peroxisome proliferator-activated receptor-gamma2 gene with type 2 diabetes mellitus]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi (2002) 0.77
Connecting the dots from fatty acids to nonalcoholic steatohepatitis: epigenetics in the spotlight. Hepatology (2013) 0.75
Increased liver enzyme levels and HNF-1beta gene mutation. Clin Gastroenterol Hepatol (2008) 0.75
The Diabetes Prevention Program and the metabolic syndrome. Ann Intern Med (2005) 0.75
Fabrication and luminescent enhancement of Eu3+-doped Y2O3@YOF core-shell nanocrystals. J Nanosci Nanotechnol (2011) 0.75
Controllable synthesis and luminescent properties of three-dimensional nanostructured CaWO4:Tb3+ microspheres. J Colloid Interface Sci (2011) 0.75
Effect of surface-absorbing chemical groups on the luminescence of Yb3+/Er3+ co-doped nanosized Y2O3. J Nanosci Nanotechnol (2010) 0.75
Recent changes in relationships between medical school physicians and industry. Gastroenterology (2010) 0.75
Hydrothermal synthesis and tunable luminescence of persimmon-like sodium lanthanum tungstate:Tb3+, Eu3+ hierarchical microarchitectures. J Colloid Interface Sci (2012) 0.75
Hepatorenal syndrome. Definition, pathophysiology, and intervention. Crit Care Clin (2002) 0.75
Identification and full-length molecular characterization of rare hepatitis C virus genotype 5a from India. Arch Virol (2014) 0.75
Quantum efficiency and surface passivation effect of nanocrystalline Y2O3:Eu3+. J Nanosci Nanotechnol (2008) 0.75
Co-precipitation synthesis and characterization of Bi3+, Eu3+ co-doped nanocrystal Gd2WO6 phosphors. J Nanosci Nanotechnol (2010) 0.75
Diagnostic modalities for the evaluation of anomalous left main coronary arteries. Cardiovasc Revasc Med (2005) 0.75
Procoagulant abnormalities in cirrhosis with portal vein thrombosis. Indian J Gastroenterol (2014) 0.75
Study of Carnitine/Acylcarnitine and Aminoacid Profile in children and adults with Acute Liver Failure. J Pediatr Gastroenterol Nutr (2016) 0.75